Metabolic & Cardiometabolic
tirzepatide causes greater weight loss than semaglutide
In plain terms: Does tirzepatide (Zepbound/Mounjaro) take off more weight than semaglutide (Wegovy/Ozempic)?
Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.63
Yes — the head-to-head SURMOUNT-5 trial and network meta-analyses show tirzepatide produces several percentage points more weight loss than semaglutide.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
16 support 1 contradict 2 tested null 4 mixed · 23 sources, 17 independent groups · 1 superseded — pooled inside a review, counted once
The evidence (24)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Cetiner S. 2026 · study_type: observational | observational | supports | low | Real-world, non-diabetic obesity, n small single-center (Istanbul): tirzepatide produced greater 36-week weight loss than semaglutide and liraglutide (exact % not given, p<0.01 for all-arm weight reduction). |
| Brown A et al 2026 · study_type: observational | observational | supports | moderate | Real-world two-center cohort: per-protocol 1y TWL semaglutide 7.2% vs tirzepatide 11.7% (and consistent at 2-3y); ITT showed similar direction. |
| Johansson E et al] # corrected 2026-08-17 from PubMed; was [Wang 2026 · J Med Econ | observational | supports | low | Cost-effectiveness analysis built on SURMOUNT-5 confirms greater weight loss with tirzepatide as its efficacy premise. |
| McGowan 2025 · Nat Med | meta-analysis | supports | high | SR/MA of obesity pharmacotherapy: tirzepatide ranks above semaglutide for weight loss magnitude. |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | high | ACP living NMA: tirzepatide among most efficacious for weight loss, ahead of semaglutide. |
| Lin RT et al] # corrected 2026-08-17 from PubMed; was [Zhou 2024 · Metabolism | meta-analysis | supports | moderate | MASLD NMA ranks GLP-1/GIP polyagonists above GLP-1RA on weight, consistent with tirzepatide>semaglutide. |
| Murugadoss K et al 2026 · Preprints.org | observational | supports | low | Sustained low-dose (0.25mg semaglutide vs 2.5mg tirzepatide) real-world comparison: tirzepatide associated with greater weight loss at low/starter doses (exact % not given). |
| de Mesquita 2023 · Int J Obes | meta-analysis | supports | moderate | MA of tirzepatide RCTs: large dose-dependent weight loss (up to ~21%), exceeding typical semaglutide magnitudes. |
| La Vignera S et al 2026 · study_type: RCT | RCT | mixed | low | Small pilot RCT (n=90), 'optimal responder' subgroups: mean weight loss 18.2%±2.1% tirzepatide vs 16.8%±1.9% semaglutide; not an overall arm comparison. |
| Venkatakrishnan AJ et al 2026 · study_type: observational | observational | supports | moderate | Large propensity-matched real-world cohort (n=10,339 each): tirzepatide -14.7% vs semaglutide -10.8% over 2y, P<0.001; high-response rate nearly doubled with tirzepatide. |
| Nong K et al 2026 · study_type: meta-analysis | meta-analysis | mixed | high | NMA of 262 RCTs: at 1y vs lifestyle mod, tirzepatide MD -14.9% (-16.0,-13.9) vs subcutaneous semaglutide -9.8% (-10.6,-9.1) -- indirect comparison, not tirzepatide-vs-semaglutide arm. |
| Builes-Montaño CE et al 2026 · study_type: RCT | RCT | contradicts | moderate | Model-based analysis of RCT dose-response data: high probability of equivalence for semaglutide 2.4mg vs tirzepatide 10mg (99.4%) and 7.2mg vs 15mg (94.8%); equivalence driven by dose not drug identity. |
| Leslie DB et al 2026 · study_type: observational | observational | supports | moderate | Real-world Epic Cosmos cohort: adjusted probability of ≥20% weight loss + HbA1c<5.7% at 1y was 3.0% semaglutide vs 13.2% tirzepatide vs 24.0% sleeve gastrectomy. |
| Aronne 2024 · JAMA | RCT | supports | moderate | SURMOUNT-4: tirzepatide lead-in achieved 20.9% loss over 36wk, exceeding semaglutide STEP magnitudes (indirect). |
| Ghosal S et al] # corrected 2026-08-17 from PubMed; was [Verma 2026 · Eur Heart J Open | observational | tested-null | low | SURMOUNT-5 post-hoc: predicted greater CV risk reduction with tirzepatide tracks its larger weight-loss effect. |
| Matson R et al 2026 · Preprints.org | observational | mixed | low | T1D real-world: 12mo weight change -4.0% semaglutide vs -6.8% tirzepatide (both vs +... controls); not the primary study endpoint (insulin dose reduction was primary). |
| Wilding 2021 · N Engl J Med | RCT | supports | moderate | STEP-1 anchor: semaglutide 2.4mg ~14.9% loss — the benchmark SURMOUNT-5 tirzepatide (-20.2%) exceeds head-to-head. ↩ SUPERSEDED — pooled in the review above, counted once |
| Al Ozairi E et al 2026 · study_type: observational | observational | supports | low | T1D real-world cohort: tirzepatide -10.9% vs semaglutide -9.9% vs liraglutide -7.1% at 12mo (all p<0.001); dose-dependent reductions noted. |
| Frias 2021 · N Engl J Med | RCT | mixed | high | SURPASS-2 (T2D): tirzepatide beat semaglutide on HbA1c and weight, BUT comparator semaglutide was 1mg, not the 2.4mg obesity dose. |
| Kitamoto T et al 2026 · study_type: RCT | RCT | supports | moderate | SURMOUNT-5 subpopulation (JASO obesity-disease criteria), Wk72: tirzepatide -20.1% vs semaglutide -12.9%, LSM diff -7.2 (95% CI -9.3 to -5.1), p<.001. |
| Ghusn W et al 2026 · study_type: observational | observational | supports | moderate | Real-world multicenter, 12mo TBWL%: tirzepatide 16.6%±8.6% vs semaglutide 13.4%±8.0%, P<.01; more tirzepatide users reached ≥15%/≥20% thresholds. |
| Xie 2025 · Diabetes Metab Syndr Obes | meta-analysis | tested-null | moderate | SR comparing GLP-1/GIP co-agonists vs GLP-1RA: greater weight loss with co-agonists, offset by more GI adverse events. |
| Hamarsheh 2026 · Endocrinol Diabetes Metab | meta-analysis | supports | moderate | NMA: tirzepatide (and CagriSema) yield greater weight reduction than semaglutide; indirect comparisons. |
| Aronne 2025 · N Engl J Med | RCT | supports | high | SURMOUNT-5 head-to-head (obesity, no diabetes): tirzepatide -20.2% vs semaglutide -13.7% at wk72 (P<0.001); superior on all weight thresholds. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.